FDA recall of repackaged ibuprofen oral syringes for cross-contamination

The FDA's recall listing of 2 September 2026 records an ongoing, not yet classified recall of ibuprofen oral suspension, 20 mg per mL, supplied as 12 mL unit-dose oral syringes delivering 7.5 mL (150 mg), berry flavoured and alcohol free. The recalling firm is Safecor Health, a repackager. The stated reason is cross-contamination with other products.

Two details set how much weight to give this. Not yet classified means the FDA has not decided whether this is a Class I, II or III recall - that is, whether the defect is likely to cause serious harm, temporary harm, or none - so the health consequence is genuinely unknown at this point rather than reassuringly small. And the problem lies in repackaging, not in the drug: the concern is what else may be in the syringe, not the ibuprofen.

For an orthopaedic service the relevance is unit-dose analgesia on the ward, particularly for children and for adults who cannot swallow tablets. If your pharmacy sources US-repackaged unit-dose oral syringes, ask them to check the firm and lot against the FDA listing. This is a US action by a US repackager and has no direct bearing on Indian supply; CDSCO has said nothing about it, and inventing an Indian angle here would be worse than leaving the space empty.

• Ask pharmacy whether any unit-dose oral syringes on the ward come from a US repackager.
• Treat not yet classified as unknown risk, not low risk, until the FDA assigns a class.
• The defect is in repackaging, so the concern is contamination rather than the ibuprofen itself.
• Nothing here changes Indian supply or CDSCO status.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.